Acelrx pharmaceuticals announces anesthesiology® 2022 annual meeting presentation on dsuvia® for battlefield analgesia by the uniformed services university of the health sciences

Presentation concludes that future battlefield medicine efforts should focus on newer analgesics like dsuvia® across military settings and establish protocols for their implementation in the trauma setting hayward, calif. , oct. 25, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract entitled, "evolution of opioid analgesia on the battlefield for moderate-to-severe acute pain" (abstract # a4123) was presented by lead author, sharon kim, m.s.
ACRX Ratings Summary
ACRX Quant Ranking